Published in Circulation on November 04, 2003
Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ (2005) 2.23
The role of ST-segment elevation in lead aVR in the risk assessment of patients with acute pulmonary embolism. Clin Res Cardiol (2011) 1.01
Regional right ventricular dysfunction in acute pulmonary embolism: relationship with clot burden and biomarker profile. Int J Cardiovasc Imaging (2015) 0.98
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers. Vasc Health Risk Manag (2009) 0.91
Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.87
Diagnosis of pulmonary embolism in the coronary care unit. Am J Cardiol (2009) 0.85
[Pulmonary embolism]. Wien Med Wochenschr (2008) 0.82
When to perform CTA in patients suspected of PE? Eur Radiol (2007) 0.82
Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients. BMC Pulm Med (2013) 0.80
Assessment of Prognostic Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Patients with Pulmonary Embolism. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.78
Cardiac biomarkers in the intensive care unit. Ann Intensive Care (2012) 0.77
Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism. J Cell Mol Med (2013) 0.76
Significance of serum cardiac troponin I levels in pulmonary embolism. J Thorac Dis (2012) 0.75
Comparison of PESI, echocardiogram, CTPA, and NT-proBNP as risk stratification tools in patients with acute pulmonary embolism. Indian Heart J (2016) 0.75
Serum myoglobin in pulmonary embolism. Circulation (2004) 0.75
Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis. Clin Transl Sci (2015) 0.75
Outcome of thrombolysis for massive pulmonary embolism. Ghana Med J (2009) 0.75
Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism. Thorac Cancer (2015) 0.75
Massive pulmonary embolus with hemodynamic compromise: therapeutic options. Emerg Radiol (2006) 0.75
Comparison of clinical scores for identification of patients with pulmonary embolism at intermediate-high risk of adverse clinical outcome: the prognostic role of plasma lactate. Intern Emerg Med (2016) 0.75
Clinical utility of the plasma brain natriuretic peptide level in monitoring tetralogy of fallot patients over the long term after initial intracardiac repair: considerations for pulmonary valve replacement. Pediatr Cardiol (2014) 0.75
Clinical application of the Innovance D-dimer assay in the diagnosis of acute pulmonary thromboembolism. Exp Ther Med (2017) 0.75
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg (2005) 2.53
Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department. Radiology (2011) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (2011) 2.34
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Massive pulmonary embolism. Circulation (2006) 2.27
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med (2002) 2.25
Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation (2004) 2.21
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Upper-extremity deep vein thrombosis. Circulation (2002) 2.09
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation (2004) 2.05
Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation (2004) 1.97
Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA (2005) 1.82
Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med (2005) 1.76
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation (2007) 1.75
Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol (2002) 1.75
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation (2009) 1.66
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
Surgical pulmonary embolectomy: the resurrection of an almost discarded operation. Tex Heart Inst J (2013) 1.63
Percutaneous mechanical thrombectomy for acute pulmonary embolism: a double-edged sword. Chest (2007) 1.60
International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med (2004) 1.55
Assessing the prognosis of acute pulmonary embolism: tricks of the trade. Chest (2008) 1.54
Medication use evaluation: pharmacist rubric for performance improvement. Pharmacotherapy (2014) 1.52
Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost (2011) 1.52
Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med (2011) 1.48
Acute pulmonary embolectomy: a contemporary approach. Circulation (2002) 1.44
Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol (2005) 1.42
Diagnosis of acute pulmonary embolism: always be vigilant. Am J Med (2007) 1.41
Cardiac decortication (epicardiectomy) for occult constrictive cardiac physiology after left extrapleural pneumonectomy. Chest (2002) 1.40
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
Improving clinical effectiveness in thromboprophylaxis for hospitalized medical patients. Am J Med (2009) 1.39
Optimal duration of anticoagulation after venous thromboembolism: fixed and evidence-based, or flexible and personalized? Ann Intern Med (2009) 1.36
Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol (2005) 1.34
Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation (2003) 1.32
Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. J Nucl Cardiol (2007) 1.31
CT signs of right ventricular dysfunction: prognostic role in acute pulmonary embolism. JACC Cardiovasc Imaging (2011) 1.30
Multislice computed tomography for pulmonary embolism--a technological marvel. N Engl J Med (2005) 1.28
Fibrinolysis for acute pulmonary embolism. Vasc Med (2010) 1.27
Management of massive pulmonary embolism. Circulation (2005) 1.27
Routine pelvic and lower extremity CT venography in patients undergoing pulmonary CT angiography. AJR Am J Roentgenol (2008) 1.22
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost (2010) 1.21
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20
Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol (2011) 1.19
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost (2005) 1.19
Acute pulmonary embolism: part II: treatment and prophylaxis. Circulation (2006) 1.16
Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring) (2009) 1.14
Time-resolved MR angiography: a primary screening examination of patients with suspected pulmonary embolism and contraindications to administration of iodinated contrast material. AJR Am J Roentgenol (2007) 1.14
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med (2007) 1.14
Delays in diagnosis of deep vein thrombosis and pulmonary embolism. Chest (2005) 1.13
Spiral computed tomography for acute pulmonary embolism. Circulation (2004) 1.12
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Venous thromboembolism in patients with active cancer. Thromb Haemost (2007) 1.09
Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. Am J Med (2010) 1.07
Pulmonary embolism: risk assessment and management. Eur Heart J (2012) 1.07
Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol (2004) 1.05
Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation (2005) 1.04
Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost (2005) 1.04
Venous thromboembolism in children. Circulation (2006) 1.04
Major bleeding complications in a specialized anticoagulation service. Am J Cardiol (2005) 1.03
Management of submassive pulmonary embolism. Circulation (2010) 1.03
Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg (2010) 1.02
The acutely decompensated right ventricle: pathways for diagnosis and management. Chest (2005) 1.02
Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest (2007) 1.02
Time trends in warfarin-associated hemorrhage. Am J Cardiol (2004) 1.02
Clinical gestalt and the diagnosis of pulmonary embolism: does experience matter? Chest (2005) 1.02
Acute pulmonary embolism: part I: epidemiology and diagnosis. Circulation (2006) 1.02
Venous thromboembolic disease. J Natl Compr Canc Netw (2013) 1.01
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J (2009) 1.00
Comparison of ECG-gated versus non-gated CT ventricular measurements in thirty patients with acute pulmonary embolism. Int J Cardiovasc Imaging (2008) 1.00
Electronic alerts for hospitalized high-VTE risk patients not receiving prophylaxis: a cohort study. J Thromb Thrombolysis (2007) 0.99
Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. Thromb Haemost (2005) 0.99
Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med (2006) 0.99
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98
Venous thromboembolism and atherothrombosis: an integrated approach. Circulation (2010) 0.97
Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost (2009) 0.96
Periprocedural management of the chronically anticoagulated patient: critical pathways for bridging therapy. Crit Pathw Cardiol (2003) 0.96
Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. J Thromb Thrombolysis (2007) 0.96
Laboratory thrombophilias and venous thromboembolism. Vasc Med (2002) 0.96
Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 0.96
Anticoagulation-associated adverse drug events. Am J Med (2011) 0.96